249 related articles for article (PubMed ID: 24766298)
1. Evolving therapies for non-alcoholic steatohepatitis.
Tilg H; Moschen AR
Expert Opin Drug Discov; 2014 Jun; 9(6):687-96. PubMed ID: 24766298
[TBL] [Abstract][Full Text] [Related]
2. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Lonardo A
Adv Ther; 2016 Mar; 33(3):291-319. PubMed ID: 26921205
[TBL] [Abstract][Full Text] [Related]
3. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
4. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
Rotman Y; Sanyal AJ
Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
[TBL] [Abstract][Full Text] [Related]
5. [Treatment Options in Non-alcoholic Fatty Liver Disease].
Kim W
Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
[TBL] [Abstract][Full Text] [Related]
7. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
8. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Sanyal AJ
Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
[TBL] [Abstract][Full Text] [Related]
9. Liver-targeting drugs and their effect on blood glucose and hepatic lipids.
Gastaldelli A; Stefan N; Häring HU
Diabetologia; 2021 Jul; 64(7):1461-1479. PubMed ID: 33877366
[TBL] [Abstract][Full Text] [Related]
10. Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Sumida Y; Yoneda M; Ogawa Y; Yoneda M; Okanoue T; Nakajima A
Expert Opin Pharmacother; 2020 Jun; 21(8):953-967. PubMed ID: 32237916
[TBL] [Abstract][Full Text] [Related]
11. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
Sun X; Zhang Y; Xie M
Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
[TBL] [Abstract][Full Text] [Related]
12. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
13. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis.
Colca JR; McDonald WG; Adams WJ
Expert Opin Investig Drugs; 2018 Jul; 27(7):631-636. PubMed ID: 29950116
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.
Shah RA; Alkhouri N; Kowdley KV
Expert Opin Emerg Drugs; 2020 Sep; 25(3):251-260. PubMed ID: 32686578
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
Liu J; Wang G; Jia Y; Xu Y
Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109
[TBL] [Abstract][Full Text] [Related]
16. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Cariou B; Staels B
Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
[TBL] [Abstract][Full Text] [Related]
17. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
Mintziori G; Polyzos SA
Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
19. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
20. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Ogawa Y; Yoneda M; Kobayashi T; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A
Expert Opin Pharmacother; 2019 Jan; 20(1):69-82. PubMed ID: 30411635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]